{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'A supportive analysis to assess the treatment effect of dupilumab if patients', 'adhere to the treatment and background asthma medication as directed is', 'also provided. In this approach, the severe exacerbation events reported after', 'the premature treatment discontinuation will be excluded from the analysis.', 'Any measurement obtained after the first permanent step up of background', 'asthma medication will also be excluded from the analysis. The supportive', 'analysis will be performed in the type 2 inflammatory phenotype and baseline', 'blood eosinophils >300 cells/L populations and will use a negative binomial', 'model with the same set of covariates as specified for the primary analysis in', 'the two populations. This model will include severe exacerbation events', 'occurring during the treatment epoch before any permanent stepping-up of', 'background asthma medication as the response variable and the log', 'transformed duration of the treatment or from randomization to first', 'permanent stepping-up of background asthma medication whichever is', 'shorter will be the offset variable.', 'The analysis of the primary endpoint will be conducted in the type 2', 'inflammatory phenotype, baseline blood eosinophils >300 cells/L, baseline', 'blood eosinophils >150 cells/L, baseline FeNO 20 ppb, and full ITT', 'populations using appropriate multiplicity control.', 'Multiplicity considerations', 'The hypothesis testing on the primary endpoint of annualized severe', 'exacerbation rate will be controlled with a two-sided type I error of 0.05 by', 'incorporating a sequential testing procedure as below:', 'For US and US reference countries:', '1st: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with baseline blood', 'eosinophils 300 cells/L.', '2nd: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with baseline blood', 'eosinophils >150 cells/L.', '3rd: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with type 2', 'inflammatory phenotype (baseline blood eosinophils -150 cells/L or', 'baseline FeNO >20 ppb).', 'For EU and EU reference countries:', '1st: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with type 2', 'inflammatory phenotype (baseline blood eosinophils 150 cells/L or', 'baseline FeNO >20 ppb).', '2nd: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with baseline blood', 'eosinophils >150 cells/L population.', '3rd: Annualized rate of severe exacerbation events during the 52-week', 'placebo-controlled treatment period based on the patients with baseline blood', 'eosinophils >300 cells/L population.', 'Multiplicity control for any secondary endpoints if considered will be specified', 'in the SAP. Otherwise, nominal p-values will be provided.', 'Handling of missing data', 'If patients withdraw from the study before Week 52 with severe exacerbation', 'events that may occur after study discontinuation, these patients are', 'considered as patients with missing data on severe exacerbation. Number,', 'Property of the Sanofi Group - strictly confidential', 'Page 17', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'reasons and timing of the missing data will be summarized by treatment', 'groups. In the primary analysis, all observed data will be used regardless of', 'treatment adherence or increase of asthma background medication. No', 'imputation will be conducted for the missing severe exacerbation information', 'after a patient prematurely withdraws from the study up to Week 52. In', 'addition, sensitivity analyses based on pattern mixture model, placebo based', 'pattern mixture model and tipping point analysis based on the same negative', 'binomial model as being used in the primary analysis may be conducted to', 'assess the robustness of the conclusion of the main model. Details of these', 'sensitivity analyses will be described in the SAP.', 'Analysis of other secondary endpoints', 'The change from baseline for continuous endpoints will be analyzed using a', 'mixed-effect model with repeated measures (MMRM) approach. The model', 'will include change from baseline as response variables, and for treatment,', 'age, weight (<30kg, >30kg), region, baseline eosinophil level (<300 cells/L,', '>300 cells/L), baseline FeNO level (<20 ppb, >20 ppb), baseline ICS dose', 'level (medium/high), visit, treatment-by-visit interaction, baseline value, and', 'baseline-by-visit interaction as covariates; unless otherwise specified (details', 'will be documented in SAP). Sex, height, and ethnicity will also be included as', 'covariates in the models for spirometry parameters. An unstructured', 'correlation matrix will be used to model the within-patient errors. Parameters', 'will be estimated using restricted maximum likelihood method using the', 'Newton-Raphson algorithm. Statistical inferences on treatment comparisons', 'for the change from baseline at Weeks 12 will be derived from the mixed-', 'effect model with Kenward and Roger degree of freedom adjustment', 'approach. Treatment comparisons at other timepoints, 8, 12, 24, 36 and 52', 'Week and other timepoints in between will also be provided from the mixed-', 'effect model for descriptive purpose. Data up to Week 52 will be included as', 'response variables.', 'Time to first severe asthma exacerbation event and time to first LOAC will be', 'analyzed using a Cox regression model with time-to-event as the dependent', 'variable, and treatment, age, weight (<30kg, >30kg), region, baseline', 'eosinophil level (<300 cells/L, >300 cells/L), baseline FeNO level (<20 ppb,', '>20 ppb), baseline ICS dose level (medium/high) and number of asthma', 'events prior to the study as covariates. The estimated hazard ratio (dupilumab', 'versus placebo) along with its 95% confidence interval will be presented. The', 'Kaplan-Meier method will be used to derive the proportion of patients with a', 'severe asthma exacerbation event at Weeks 12, 24, 36, and 52, specific to', 'each treatment group.', 'The safety variables, including AEs, laboratory parameters, vital signs, ECG,', 'and physical examinations will be summarized using descriptive statistics.', 'The analysis of safety variables will be performed based on the safety', 'population.', 'Interim Analysis', 'There is no interim analysis planned for this study.', 'Planned database lock', 'The database lock is planned based on the time when all randomized patients', 'reach complete week 52 visit or discontinue from the study before week 52.', 'Analyses will be based on all data collected up to this database lock and will', 'be considered as the final analyses in the CSR (Clinical Study Report).', 'Additional data between database lock and last patient completing last visit', 'will be summarized in a CSR addendum.', 'Property of the Sanofi Group - strictly confidential', 'Page 18', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}